skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Oral Hsp90 Inhibitor IPI-493 (Code C78843)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Oral Hsp90 Inhibitor IPI-493

Definition: An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or "client" proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors.

Display Name: Oral Hsp90 Inhibitor IPI-493

Label: Oral Hsp90 Inhibitor IPI-493

NCI Thesaurus Code: C78843 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703137  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Heat Shock Protein 90 Inhibitor IPI-493
Oral Hsp90 Inhibitor IPI-493

External Source Codes: 
NSC Code 255109 (see NCI DTP info)
PDQ Closed Trial Search ID 610131
PDQ Open Trial Search ID 610131 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703137

Other Properties:
     Name Value (qualifiers indented underneath)
code C78843
Contributing_Source CTRP
Legacy_Concept_Name Hsp90_Inhibitor_IPI-493
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom